The Market's Junk Drawer: Sifting Through AI Hypes, Biotech Bets, and Failing TractorsGlobal Report·2 days ago, 05:12 AMSBGSY-0.28%PHM+1.39%
Ocular Therapeutix grants inducement awards to new hires, including options priced at $8.4 per sharePUBT·Aug 7 at 03:05 PMOCUL+0.24%
Ocular Therapeutix Faces Governance and Perception Risks from Insider Equity Compensation and Trading PracticesTip Ranks·Aug 4 at 01:00 AMOCUL+0.24%
Ocular Therap | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 13.48 MEarnings Watch·Aug 3 at 06:09 AMOCUL+0.24%
Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business HighlightsUnusual Whales·Aug 3 at 06:03 AMOCUL+0.24%
Ocular Therapeutix Q2 FY26 net loss widens to $78.76 million; revenue rises 0.12% to $13.48 millionPUBT·Aug 3 at 06:02 AMOCUL+0.24%
Readystate Asset Management LP Makes New Investment in Ocular Therapeutix, Inc. $OCULMarket Beat·Jul 29 at 05:24 AMOCUL+0.24%
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Consensus Rating of "Moderate Buy" from BrokeragesMarket Beat·Jul 28 at 01:44 AMOCUL+0.24%
Ocular Therapeutix grants new hires options for 34,700 shares at $9.66 eachPUBT·Jul 9 at 03:05 PMOCUL+0.24%
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Unusual Whales·Jun 22 at 03:08 PMOCUL+0.24%
